Table 5.
Species | Chemical | Method of Administation | Incidence GF % | Incidence CV/CVz % | Medical Conditions | Strain | Gender | n. of Animals | Age (Weight) of Animals at the Start of Experiment | Year | Citation |
---|---|---|---|---|---|---|---|---|---|---|---|
Mice | DSS 5% and 1% | Orally—drinking water | 84% | 10% | colitis | IQI/Jic | ♀ | 19 (−6†) GF | 6–7 weeks | 2001 | [74] |
10 CVz | |||||||||||
DSS 2.5% | orally—drinking water | 53% | 44% | acute and chronic colitis | BALB/c | 15 (−5†) GF | 6–7 weeks | 2001 | [77] | ||
18 (−4†) CV | |||||||||||
75% | 86% | SCID | 16 (−8†) GF | ||||||||
14 (−6†) CV | |||||||||||
AOM (10 mg/kg), DSS 1–2.5% | orally—drinking water | 100% * | 0% * | colitis | C57BL/6 | GF | 6–12 weeks | 2013 | [82] | ||
CV | |||||||||||
Guinea pigs | Carrageenan 5% | orally—drinking water | 0% | 100% | Cecal ulceration | Hartley strain guinea pigs | ♂ | 6 GF | 250–300 g | 1981 | [72] |
142 CV |
Acronyms:.DSS: dextran sodium sulphate; AOM: azoxymethane; SCID: severe combined immundeficiency. * mortality after DSS >2%